Trial Profile
A Randomized, Active-controlled, Double-blinded, Double-dummy, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Dialysis Subjects Treated With Erythropoiesis-Stimulating Agents (ESAs)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Molidustat (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms MIYABI HD-M
- Sponsors Bayer
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183972).
- 15 Jan 2020 Status changed from active, no longer recruiting to completed.
- 15 Nov 2019 Planned End Date changed from 31 Dec 2019 to 24 Dec 2019.